DMAA — Drugs Made In America Acquisition Income Statement
0.000.00%
Last trade - 00:00- $337.18m
- $337.84m
Annual income statement for Drugs Made In America Acquisition, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | ARS | 10-K |
| Standards: | — | USG |
| Status: | Final | Final |
| Total Revenue | 0 | 0 |
| Selling / General / Administrative Expenses | ||
| Total Operating Expenses | — | 0.28 |
| Operating Profit | 0 | -0.28 |
| Net Income Before Taxes | — | -0.28 |
| Net Income After Taxes | — | -0.28 |
| Net Income Before Extraordinary Items | ||
| Net Income | — | -0.28 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Dilution Adjustment | ||
| Diluted Net Income | 0 | -0.28 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | — | -0.013 |